The multinational pharmaceutical giant Lupin Limited has announced that it will expand its diabetes portfolio in the nation by acquiring the anti-diabetic trademarks GIBTULIO, GIBTULIO MET, and AJADUO from BoehringerIngelheim International GmbH. According to the agreement, Lupin will receive the trademark rights for these brands by March of the following year. In the Indian market, Lupin has been selling GIBTULIO and GIBTULIO MET since 2016 and AJADUO since 2018 thanks to co-marketing agreements with Boehringer Ingelheim India.
Lupin Acquisition
In order to expand its diabetic portfolio in India, Lupin Limited has announced that it has acquired three important trademarks from Boehringer Ingelheim. Gibtulio (empagliflozin), Gibtulio Met (empagliflozin + metformin), and Ajaduo (empagliflozin + linagliptin) are among the trademarks. It is anticipated that the rights will be transferred by March 2025. According to a press release posted on the stock exchanges, Lupin has been co-marketing these drugs since 2016 and the complete transfer will strengthen its position in the Indian diabetic market.
Lupin Share Price
The share price of Lupin, a largecap on the BSE and a player in the pharmaceutical industry, is currently at 2066.5. Today, the stock has fluctuated, reaching a low of ₹2059 and a high of ₹2095.45. The shares have fluctuated between a low of ₹1200.35 and a high of ₹2312 over the last 52 weeks. Performance-wise, Lupin has returned -0.44% in a single day, 2.63% in the previous month, and -8.25% in the previous three months.
About the Company – Lupin Ltd
Lupin is a transnational pharmaceutical company that leads innovation in the production, development, and marketing of a broad range of active pharmaceutical ingredients (APIs), biotechnology products, and branded and generic formulations worldwide. The company is a global leader in the anti-TB and cephalosporins segments and a major participant in the Cardiovascular Diabetology Asthma Pediatric Central Nervous System (CNS) Gastro-Intestinal (GI) Anti-Infective and Nonsteroidal Anti-Inflammatory Drug (NSAID) therapy segments. In 1983, Lupin Ltd. was established under the name Lupin Chemicals Ltd.
